Dataset Information


Predicting drug responsiveness in humans cancers using genetically engineered mice

ABSTRACT: Anti-cancer drug testing is challenging, but genetically engineered mouse models (GEMMs) and orthotopic, syngeneic transplants (OSTs) may offer advantages for pre-clinical testing including an intact microenvironment. We examined the efficacy of six chemotherapeutic or targeted anti-cancer drugs, alone and in combination, using over 500 GEMMs/OSTs representing three distinct breast cancer subtypes: Basal-like (C3(1)-T-antigen GEMM), Luminal B (MMTV-Neu GEMM), and Claudin-low (T11/TP53-/- OST). While a few single agents offered exceptional efficacy like lapatinib in the Neu/ERBB2 driven model, combination therapies tended to be more active and life prolonging. Using expression profiling of chemotherapy treated murine tumors, we identified an expression signature that was able to predict pathological complete response to neoadjuvant anthracycline-taxane treated human breast cancer patients, even after accounting for the common clinical variables and other genomic signatures. These results show that credentialed murine models can predict the efficacy of would-be anti-cancer compounds in humans, and that GEMMs can be used to develop new biomarkers of therapeutic responsiveness in humans. control X treatment

ORGANISM(S): Mus musculus  

SUBMITTER: Charles Perou   Charles M Perou  Jerry Usary 

PROVIDER: E-GEOD-37915 | ArrayExpress | 2014-01-01



Similar Datasets

2012-08-21 | E-GEOD-35722 | ArrayExpress
2012-05-29 | E-GEOD-28712 | ArrayExpress
2012-06-29 | E-GEOD-28713 | ArrayExpress
2014-03-21 | E-GEOD-50555 | ArrayExpress
2013-11-04 | E-GEOD-42640 | ArrayExpress
2015-05-12 | E-GEOD-55399 | ArrayExpress
2014-07-01 | E-GEOD-50794 | ArrayExpress
2015-01-21 | E-GEOD-48073 | ArrayExpress
2010-03-09 | E-GEOD-17916 | ArrayExpress
2014-08-20 | E-GEOD-51783 | ArrayExpress